CVE:RLVRelevium Technologies Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Relevium Technologies Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add C$0.03 0.00 (0.00 %) (As of 07/2/2020 11:11 AM ET) Add Compare Share Today's RangeC$0.03Now: C$0.03▼C$0.0350-Day RangeC$0.03MA: C$0.04▼C$0.0552-Week RangeC$0.01Now: C$0.03▼C$0.09Volume87,250 shsAverage Volume979,787 shsMarket CapitalizationC$5.97 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAdvanced ChartCompetitorsInsider TradesHeadlinesSocial Media Relevium Technologies Inc. engages in the identification, evaluation, and acquisition of assets or businesses in the health and wellness markets with a focus on e-commerce. The company markets dietary supplements, nutraceuticals, sports nutrition products, and nutri cosmeceuticals primarily through its Bioganix brand portfolio online, as well as dietary supplements under the LeefyLyfe brand name through its wholesale, retail, and online distribution channels. It is also involved in the extraction, formulation, development, and encapsulation of proprietary nutraceutical products for medical purposes. The company was formerly known as BIOflex Technologies Inc. and changed its name to Relevium Technologies Inc. in December 2015. The company was incorporated in 2012 and is headquartered in Montreal, Canada. Relevium Technologies Inc. is a subsidiary of iTech Medical, Inc.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Relevium Technologies. Previous Next 2.4 Community Rank Outperform VotesRelevium Technologies has received 49 “outperform” votes. (Add your “outperform” vote.)Underperform VotesRelevium Technologies has received 55 “underperform” votes. (Add your “underperform” vote.)Community SentimentRelevium Technologies has received 52.88% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Relevium Technologies and other stocks. Vote “Outperform” if you believe RLV will outperform the S&P 500 over the long term. Vote “Underperform” if you believe RLV will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldRelevium Technologies does not currently pay a dividend.Dividend GrowthRelevium Technologies does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Relevium Technologies insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Relevium Technologies is -1.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Relevium Technologies is -1.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRelevium Technologies has a P/B Ratio of 1.07. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.48 out of 5 stars Industry, Sector and Symbol Stock Exchange CVE Industry Medical Instruments & Supplies Sub-IndustryN/A SectorMedical Current SymbolCVE:RLV Previous Symbol CUSIPN/A CIKN/A Webwww.releviumcorp.com Phone+1-514-8248559Debt Debt-to-Equity Ratio68.30 Current Ratio0.34 Quick Ratio0.20Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesC$4.20 million Price / Sales1.42 Cash FlowC$0.00 per share Price / Cash Flow30.00 Book ValueC$0.03 per share Price / Book1.07Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares198,846,000Market CapC$5.97 million Next Earnings DateN/A OptionableNot Optionable TSXV:RLV Rates by TradingView Receive RLV News and Ratings via Email Sign-up to receive the latest news and ratings for RLV and its competitors with MarketBeat's FREE daily newsletter. Relevium Technologies (CVE:RLV) Frequently Asked Questions How has Relevium Technologies' stock been impacted by COVID-19 (Coronavirus)? Relevium Technologies' stock was trading at C$0.02 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, RLV shares have increased by 100.0% and is now trading at C$0.03. View which stocks have been most impacted by Coronavirus. Has Relevium Technologies been receiving favorable news coverage? Headlines about RLV stock have been trending very negative recently, according to InfoTrie Sentiment. The research firm ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Relevium Technologies earned a coverage optimism score of -3.3 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news about Relevium Technologies. Who are some of Relevium Technologies' key competitors? Some companies that are related to Relevium Technologies include TransEnterix (TRXC), Akers Biosciences (AKR), Vigil Health Solutions (VGL), Ambu A/S (AMBBY), Ansell (ANSLF), ANSELL LTD/S (ANSLY), Commerzbank (CZMWY), CONVATEC GRP PL/ADR (CNVVY), Demant A/S (WILLF), Essilor International Cmgn Gnl D Optq (EI), Fisher & Paykel Healthcare (FSPKF), Iris BioTechnologies (IRSB), Lifestyle Delivery Systems (LDS), Lifestyle Delivery Systems (LDSYF) and Medigard (MGZ). View all competitors. What other stocks do shareholders of Relevium Technologies own? Based on aggregate information from My MarketBeat watchlists, some companies that other Relevium Technologies investors own include Arctic Star Exploration (ADD), Canopy Growth (CGC), Eldorado Gold (ELD), Freedom Leaf (FRLF), Macquarie Infrastructure (MIC), 1933 Industries (TGIF), Acquired Sales (AQSP), Aphria (APHA), Aphria (APHA) and Aldeyra Therapeutics (ALDX). Who are Relevium Technologies' key executives? Relevium Technologies' management team includes the following people: Mr. Aurelio Useche C.M.A., M.B.A., Pres, CEO & Director (Age 51)Mr. Edward Ierfino, Mang. of Investor Relations (Age 51)Mr. Wayne D. Cockburn, Consultant (Age 62)Mr. Faycal Salek, Chief Financial OfficerMr. Abis Hussain, Sr. Marketing Officer What is Relevium Technologies' stock symbol? Relevium Technologies trades on the Canadian Venture Exchange (CVE) under the ticker symbol "RLV." How do I buy shares of Relevium Technologies? Shares of RLV and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab. What is Relevium Technologies' stock price today? One share of RLV stock can currently be purchased for approximately C$0.03. How big of a company is Relevium Technologies? Relevium Technologies has a market capitalization of C$5.97 million and generates C$4.20 million in revenue each year. What is Relevium Technologies' official website? The official website for Relevium Technologies is www.releviumcorp.com. How can I contact Relevium Technologies? Relevium Technologies' mailing address is 1000 Sherbrooke St W Suite 2700, MONTREAL, QC H3A 3G4, Canada. The company can be reached via phone at +1-514-8248559. This page was last updated on 7/2/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
